Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–(BUSINESS WIRE)– Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and Life Sciences, where the instrument will support research into the biology of human diseases, the discovery of new therapeutics and advances in biotechnology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005188/en/ Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Mass spectrometry (MS) is a widely deployed analytical method used by scientists to identify and quantify molecules in a sample and determine their detailed molecular structure. For example, it can be used to more effectively identify disease biomarkers that allow for early detection. Ion mobility spectrometry is a proven technique that separates ions by their size, shape and charge. The SELECT SERIES Cyclic IMS takes ion mobility to a new level, replacing the traditional linear ion mobility region with a novel compact cyclic device. Ions traverse around the cyclic region and with every pass greater ion mobility resolution is achieved. In addition, the advanced technology enables the unique ability to perform ion mobility selection for ion mobility/ion mobility and IMSn experiments. The new instrument will be used by researchers at Aston University and across the Midland Innovation consortium to answer complex biological questions. Andrew Pitt, Professor of Pharmaceutical Chemistry & Chemical Biology, Aston University said: “We are delighted to have this new technology in our lab here at Aston; it will provide us and other researchers in the Midlands with a step change in how we conduct our research. “The new instrument is one of a relatively recent class of mass spectrometers, incorporating ion mobility, which separate molecules based not only on their mass but also by their shape. This allows us to see what is going on in biology in much more detail, including information we are able to gain from the shape of molecules that will allow us to solve much more complex questions.” Combining novel IMS capability with significantly improved mass spectrometry performance and enabling software, this platform allows leading researchers to unlock the potential in scientific discovery. Jim Langridge, Advanced MS Technologies Waters Corporation said: “Human biology is extraordinarily complex and the SELECT SERIES Cyclic IMS gives research scientists the ability to probe deeper into the chemistry and biology of human disease like never before. “By collaborating with leading researchers like Professor Pitt, we continually advance the science of mass spectrometry, accelerating their research into human health and well-being.” Aston University scientists will run a visiting researcher programme that will allow researchers from many disciplines to visit Aston and work with the first-of-its-kind SELECT SERIES Cyclic IMS instrument, exploring its unparalleled experimental potential. The journal Analytical Chemistry documented the effectiveness and power of the cyclic IMS instrument in a recent article titled: A Cyclic Ion Mobility – Mass Spectrometry System. About Aston University Founded in 1895 and a University since 1966, Aston is a long established university led by its three main beneficiaries – students, business and the professions, and our region and society. Aston University is located in Birmingham and at the heart of a vibrant city and the campus houses all the university’s academic, social and accommodation facilities for our students. Professor Alec Cameron is the Vice Chancellor & Chief Executive. About Waters Corporation Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. Waters and SELECT SERIES are trademarks of Waters Corporation.

/in , , , /by

Cambridge, UK – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls. Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses this issue by providing access to […]

Read more →

ABCELLERA ANNOUNCES THE ISSUANCE OF FOUNDATIONAL PATENT CLAIMS AROUND MICROFLUIDIC SCREENING ASSAYS FOR ANTIBODY DISCOVERY

/in , , , /by

AbCellera Biologics Inc., a global leader in therapeutic antibody discovery from natural immune systems, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent no. 10,466,241 titled “Methods for Assaying Cellular Binding Interactions.” The patent, exclusively licensed to AbCellera, originated from Carl Hansen’s former laboratory at the University of British Columbia and lists Carl […]

Read more →

Thermo Scientific Aquilos 2 Cryo-FIB Speeds Sample Preparation

/in , , , , , /by

Latest DualBeam system provides significant clarity of protein interactions HILLSBORO, Ore. — Thermo Fisher Scientific today announced the Thermo Scientific Aquilos 2 Cryo-FIB, a DualBeam system dedicated to the preparation of thin, electron-transparent samples from biological specimens. It simplifies the cryo-electron tomography (cryo-ET) workflow by reducing sample preparation time, minimizing the risk of contamination and providing a […]

Read more →

Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost

/in , /by

PUNE, India — Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The state-of-the-art manufacturing plant has a significantly smaller footprint than the conventional manufacturing facilities. Enzene is amongst the first movers in […]

Read more →

Syngene sponsors Tufts Launchpad/BioLabs to support biomedical innovation in Boston

/in , , /by

Maryland, MD: Syngene, a world-leading manufacturer of image analysis solutions, is pleased to announce it has entered a sponsorship agreement with Tufts Launchpad | BioLabs developed by Tufts University to be Boston’s premier fully equipped, co-working and shared lab space for biotech start-ups. Under the terms of the sponsorship, scientists working in biotech and life […]

Read more →

Cells that could lead to new therapies: PromoCell now offers in vitro disease models

/in , , , /by

Portfolio extension: Wide range of donor cells with common chronic diseases New models can help researchers investigate disease development and find new treatment approaches Matched growth media are optimized for pharmaceutical drug discovery Heidelberg, Germany – PromoCell, a premier manufacturer of human primary cells and cell culture products, now offers cell disease models covering a […]

Read more →

BIO-TECHNE LICENSES ATAG TECHNOLOGY FROM C4 THERAPEUTICS, INC.

/in , , , /by

MINNEAPOLIS — Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, today announced the signing of an agreement with C4 Therapeutics, Inc. to acquire an exclusive license for the Achilles-TAG (aTAG) degradation platform. The license will make aTAG technology commercially […]

Read more →

Mission Bio Launches Industry-First Single-cell Multi-omics Capabilities to Simultaneously Detect DNA and Protein from the Same Cell

/in , , , /by

As the first and only platform with these capabilities, the Tapestri Platform will enable key insights to drive the development of more impactful cancer therapies   SOUTH SAN FRANCISCO, Calif.  Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the […]

Read more →

Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®

/in , /by

Madison, WI USA.  Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) for use with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The global collaboration will initially seek regulatory […]

Read more →

Thermo Fisher Scientific Introduces First Next-Generation Sequencing Platform That Delivers Specimen to Report in a Single Day

/in , /by

Ion Torrent Genexus System* holds potential to advance precision medicine in the clinic BALTIMORE — Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. Launched at the Association for Molecular Pathology (AMP) 2019 annual […]

Read more →